Letter to Health Care Professionals Regarding Wallcur IV Solutions

Posted in Latest News on January 9, 2015.

Dear Healthcare Partners:

Florida Department of Health is requesting that health care professionals report any administration of  Wallcur IV training solutions to patients since January 1, 2014, whether the patient had adverse effects or not. Wallcur IV solution products have been distributed in Florida and have been linked to serious illness in at least one Florida resident.

FDA has become aware that some Wallcur training IV products have been distributed to health care facilities and administered to patients. There have been reports of serious adverse events associated with the use of certain of these products – i.e., Practi IV Solution Bags.

Before administering IV solutions to patients, health care providers should carefully check the labels to ensure that the products are not training products, such as Practi IV Solution Bags marketed by Wallcur. Wallcur’s training products, which may bear the words “for clinical simulation,” are not to be administered to patients. Again, Wallcur IV solutions should not be administered to people or animals.

If you suspect that any Wallcur training IV product may have been administered to a patient, whether or not the incident has resulted in an adverse event, please report the incident to:

  1. FDA’s MedWatch Adverse Event Reporting program by completing and submitting the report online at: https://www.accessdata.fda.gov/scripts/medwatch/index.cfm or completing the form online and then submitting it via fax to 1-800-FDA-0178
  2. Also report administration of Wallcur IV training products to the Florida Department of Health at 850-245-4401 .

FDA will continue to investigate and monitor this issue, and will continue working with the Centers for Disease Control and Prevention and state health departments to keep health care professionals informed.

Sincerely,
Anna M. Likos, MD, MPH, Director
Division of Disease Control and Health Protection

 

Copy of Letter from Anna M. Likos (pdf)



More Latest News

Temporary Changes to CE Requirements (COVID-19)
March 13, 2020

Today, the Florida Board of Osteopathic Medicine entered into emergency rulemaking and adopted Rule 64B15ER20-18, which waives the requirement for live, participatory attendance for certain continuing education courses for the 2018-2020 biennium, in accordance with Executive Orders 20-51 and 20-52 declaring a public health emergency pursuant to the spread of the Coronavirus Disease 2019 (COVID-19). Continue reading


New Coronavirus: COVID-19
February 17, 2020

The Florida Department of Health (Department) is working closely with the Centers for Disease Control and Prevention (CDC) to closely monitor the current outbreak of 2019 novel coronavirus. Continue reading